BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang X, Ng HLH, Lu A, Lin C, Zhou L, Lin G, Zhang Y, Yang Z, Zhang H. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future. Nanomedicine. 2016;12:853-869. [PMID: 26772424 DOI: 10.1016/j.nano.2015.12.381] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Xue D, Han J, Liang Z, Jia L, Liu Y, Tuo H, Peng Y. Current Perspectives on the Unique Roles of Exosomes in Drug Resistance of Hepatocellular Carcinoma. JHC 2022;Volume 9:99-112. [DOI: 10.2147/jhc.s351038] [Reference Citation Analysis]
2 Dimri M, Satyanarayana A. Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E491. [PMID: 32093152 DOI: 10.3390/cancers12020491] [Cited by in F6Publishing: 48] [Reference Citation Analysis]
3 Cao Y, Zhang H. Recent advances in nano material-based application of liver neoplasms. Smart Materials in Medicine 2021;2:114-23. [DOI: 10.1016/j.smaim.2021.03.001] [Reference Citation Analysis]
4 Chakraborty S, Dlie ZY, Chakraborty S, Roy S, Mukherjee B, Besra SE, Dewanjee S, Mukherjee A, Ojha PK, Kumar V, Sen R. Aptamer-Functionalized Drug Nanocarrier Improves Hepatocellular Carcinoma toward Normal by Targeting Neoplastic Hepatocytes. Mol Ther Nucleic Acids 2020;20:34-49. [PMID: 32146417 DOI: 10.1016/j.omtn.2020.01.034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
5 Leng F, Liu F, Yang Y, Wu Y, Tian W. Strategies on Nanodiagnostics and Nanotherapies of the Three Common Cancers. Nanomaterials (Basel) 2018;8:E202. [PMID: 29597315 DOI: 10.3390/nano8040202] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
6 Vène E, Jarnouen K, Ribault C, Vlach M, Verres Y, Bourgeois M, Lepareur N, Cammas-marion S, Loyer P. Circumsporozoite Protein of Plasmodium berghei- and George Baker Virus A-Derived Peptides Trigger Efficient Cell Internalization of Bioconjugates and Functionalized Poly(ethylene glycol)-b-poly(benzyl malate)-Based Nanoparticles in Human Hepatoma Cells. Pharmaceutics 2022;14:804. [DOI: 10.3390/pharmaceutics14040804] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Turato C, Balasso A, Carloni V, Tiribelli C, Mastrotto F, Mazzocca A, Pontisso P. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. J Control Release 2017;268:184-97. [PMID: 29051062 DOI: 10.1016/j.jconrel.2017.10.027] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
8 Zhang X, Lin CC, Chan WK, Liu KL, Yang ZJ, Zhang HQ. Augmented Anticancer Effects of Cantharidin with Liposomal Encapsulation: In Vitro and In Vivo Evaluation. Molecules 2017;22:E1052. [PMID: 28672816 DOI: 10.3390/molecules22071052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
9 Yan M, Dongmei B, Jingjing Z, Xiaobao J, Jie W, Yan W, Jiayong Z. Antitumor activities of Liver-targeting peptide modified Recombinant human Endostatin in BALB/c-nu mice with Hepatocellular carcinoma. Sci Rep 2017;7:14074. [PMID: 29075040 DOI: 10.1038/s41598-017-14320-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Cordeiro R, Carvalho A, Durães L, Faneca H. Triantennary GalNAc-Functionalized Multi-Responsive Mesoporous Silica Nanoparticles for Drug Delivery Targeted at Asialoglycoprotein Receptor. Int J Mol Sci 2022;23:6243. [PMID: 35682920 DOI: 10.3390/ijms23116243] [Reference Citation Analysis]
11 Yang W, Zhang Y, Wang J, Haiying L, Yang H. Glycyrrhetinic acid-cyclodextrin grafted pullulan nanoparticles loaded doxorubicin as a liver targeted delivery carrier. Int J Biol Macromol 2022:S0141-8130(22)01614-2. [PMID: 35914549 DOI: 10.1016/j.ijbiomac.2022.07.182] [Reference Citation Analysis]
12 Li C, Wu M, Zong G, Wan C, Liu Q, Zhou H, Hua L, Chen Y, Chen X, Lu C. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma. Dig Dis Sci 2017;62:133-42. [PMID: 27921263 DOI: 10.1007/s10620-016-4365-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
13 Lin Z, Miao D, Xu Q, Wang X, Yu F. A novel focal adhesion related gene signature for prognostic prediction in hepatocellular carcinoma. Aging (Albany NY) 2021;13:10724-48. [PMID: 33850056 DOI: 10.18632/aging.202871] [Reference Citation Analysis]
14 Hanck-silva G, Minatti E. Polystyrene-b-poly (acrylic acid) nanovesicles coated by modified chitosans for encapsulation of minoxidil. Braz J Pharm Sci 2022;58:e19106. [DOI: 10.1590/s2175-9790202132e19106] [Reference Citation Analysis]
15 Ma Z, Zhang B, Fan Y, Wang M, Kebebe D, Li J, Liu Z. Traditional Chinese medicine combined with hepatic targeted drug delivery systems: A new strategy for the treatment of liver diseases. Biomed Pharmacother 2019;117:109128. [PMID: 31234023 DOI: 10.1016/j.biopha.2019.109128] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
16 Li J, Wu DD, Zhang JX, Wang J, Ma JJ, Hu X, Dong WG. Mitochondrial pathway mediated by reactive oxygen species involvement in α-hederin-induced apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2018; 24(17): 1901-1910 [PMID: 29740205 DOI: 10.3748/wjg.v24.i17.1901] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
17 Khan AA, Allemailem KS, Almatroodi SA, Almatroudi A, Rahmani AH. Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications. 3 Biotech 2020;10:163. [PMID: 32206497 DOI: 10.1007/s13205-020-2144-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 16.0] [Reference Citation Analysis]
18 Jin X, Li M, Yin L, Zhou J, Zhang Z, Lv H. Tyroservatide-TPGS-paclitaxel liposomes: Tyroservatide as a targeting ligand for improving breast cancer treatment. Nanomedicine 2017;13:1105-15. [PMID: 27845234 DOI: 10.1016/j.nano.2016.10.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
19 Ma P, Yu H, Zhang X, Mu H, Chu Y, Ni L, Xing P, Wang Y, Sun K. Increased Active Tumor Targeting by An αvβ3-Targeting and Cell-Penetrating Bifunctional Peptide-Mediated Dendrimer-Based Conjugate. Pharm Res 2017;34:121-35. [DOI: 10.1007/s11095-016-2045-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
20 Lu S, Lu R, Song H, Wu J, Liu X, Zhou X, Yang J, Zhang H, Tang C, Guo H, Hu J, Mao G, Lin H, Su Z, Zheng H. Metabolomic study of natrin-induced apoptosis in SMMC-7721 hepatocellular carcinoma cells by ultra-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry. Int J Biol Macromol 2019;124:1264-73. [PMID: 30508545 DOI: 10.1016/j.ijbiomac.2018.11.060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
21 Zhu X, Tsend-ayush A, Yuan Z, Wen J, Cai J, Luo S, Yao J, Bian J, Yin L, Zhou J, Yao J. Glycyrrhetinic acid-modified TPGS polymeric micelles for hepatocellular carcinoma-targeted therapy. International Journal of Pharmaceutics 2017;529:451-64. [DOI: 10.1016/j.ijpharm.2017.07.011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
22 Fuchs K, Duran R, Denys A, Bize PE, Borchard G, Jordan O. Drug-eluting embolic microspheres for local drug delivery - State of the art. J Control Release 2017;262:127-38. [PMID: 28710006 DOI: 10.1016/j.jconrel.2017.07.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
23 Wang H, Ellipilli S, Lee WJ, Li X, Vieweger M, Ho YS, Guo P. Multivalent rubber-like RNA nanoparticles for targeted co-delivery of paclitaxel and MiRNA to silence the drug efflux transporter and liver cancer drug resistance. J Control Release 2021;330:173-84. [PMID: 33316298 DOI: 10.1016/j.jconrel.2020.12.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
24 Jiang Y, Liu X, Tan X, Hou Y, Sun W, Gou J, Yin T, He H, Zhang Y, Tang X. In Vitro and In Vivo Evaluation of SP94 Modified Liposomes Loaded with N-14NCTDA, a Norcantharimide Derivative for Hepatocellular Carcinoma-Targeting. AAPS PharmSciTech 2020;21:277. [PMID: 33033942 DOI: 10.1208/s12249-020-01829-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Baig B, Halim SA, Farrukh A, Greish Y, Amin A. Current status of nanomaterial-based treatment for hepatocellular carcinoma. Biomedicine & Pharmacotherapy 2019;116:108852. [DOI: 10.1016/j.biopha.2019.108852] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 11.7] [Reference Citation Analysis]
26 Yang N, Li S, Li G, Zhang S, Tang X, Ni S, Jian X, Xu C, Zhu J, Lu M. The role of extracellular vesicles in mediating progression, metastasis and potential treatment of hepatocellular carcinoma. Oncotarget. 2017;8:3683-3695. [PMID: 27713136 DOI: 10.18632/oncotarget.12465] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
27 Zhao P, Malik S, Xing S. Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC). Front Oncol 2021;11:677926. [PMID: 34336665 DOI: 10.3389/fonc.2021.677926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Huang D, Chen Z, Yang Y, Jiang L, Liu Y, Yang Y, Zhang C. Enhanced Embolization Efficacy with the Embolic Microspheres Guided by the Aggregate Gradation Theory Through In Vitro and Simulation Evaluation. Cardiovasc Eng Technol 2021;12:398-406. [PMID: 33844137 DOI: 10.1007/s13239-021-00534-x] [Reference Citation Analysis]
29 Lu J, Wang J, Ling D. Surface Engineering of Nanoparticles for Targeted Delivery to Hepatocellular Carcinoma. Small 2018;14. [PMID: 29251419 DOI: 10.1002/smll.201702037] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
30 Gong Y, Wu X, Wang T, Zhao J, Liu X, Yao Z, Zhang Q, Jian X. Targeting PEPT1: a novel strategy to improve the antitumor efficacy of doxorubicin in human hepatocellular carcinoma therapy. Oncotarget 2017;8:40454-68. [PMID: 28465466 DOI: 10.18632/oncotarget.17117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
31 Sathiyaseelan A, Saravanakumar K, Wang MH. Cerium oxide decorated 5-fluorouracil loaded chitosan nanoparticles for treatment of hepatocellular carcinoma. Int J Biol Macromol 2022:S0141-8130(22)01316-2. [PMID: 35750101 DOI: 10.1016/j.ijbiomac.2022.06.112] [Reference Citation Analysis]
32 Li M, Zhang W, Wang B, Gao Y, Song Z, Zheng QC. Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma. Int J Nanomedicine 2016;11:5645-69. [PMID: 27920520 DOI: 10.2147/IJN.S115727] [Cited by in Crossref: 67] [Cited by in F6Publishing: 25] [Article Influence: 11.2] [Reference Citation Analysis]
33 Liu Y, Xia X, Wang Y, Li X, Zhou G, Liang H, Feng G, Zheng C. Screening and identification of a specific peptide for targeting hypoxic hepatoma cells. Molecular and Cellular Probes 2016;30:246-53. [DOI: 10.1016/j.mcp.2016.06.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Reshitko GS, Yamansarov EY, Evteev SA, Lopatukhina EV, Shkil' DO, Saltykova IV, Lopukhov AV, Kovalev SV, Lobov AN, Kislyakov IV, Burenina OY, Klyachko NL, Garanina AS, Dontsova OA, Ivanenkov YA, Erofeev AS, Gorelkin PV, Beloglazkina EK, Majouga AG. Synthesis and Evaluation of New Trivalent Ligands for Hepatocyte Targeting via the Asialoglycoprotein Receptor. Bioconjug Chem 2020;31:1313-9. [PMID: 32379426 DOI: 10.1021/acs.bioconjchem.0c00202] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Petrov RA, Maklakova SY, Ivanenkov YA, Petrov SA, Sergeeva OV, Yamansarov EY, Saltykova IV, Kireev II, Alieva IB, Deyneka EV, Sofronova AA, Aladinskaia AV, Trofimenko AV, Yamidanov RS, Kovalev SV, Kotelianski VE, Zatsepin TS, Beloglazkina EK, Majouga AG. Synthesis and biological evaluation of novel mono- and bivalent ASGP-R-targeted drug-conjugates. Bioorg Med Chem Lett 2018;28:382-7. [PMID: 29269214 DOI: 10.1016/j.bmcl.2017.12.032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
36 Zhou C, Xia Y, Wei Y, Cheng L, Wei J, Guo B, Meng F, Cao S, van Hest JCM, Zhong Z. GE11 peptide-installed chimaeric polymersomes tailor-made for high-efficiency EGFR-targeted protein therapy of orthotopic hepatocellular carcinoma. Acta Biomater 2020;113:512-21. [PMID: 32562803 DOI: 10.1016/j.actbio.2020.06.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
37 Jiang B, Zhang R, Zhang J, Hou Y, Chen X, Zhou M, Tian X, Hao C, Fan K, Yan X. GRP78-targeted ferritin nanocaged ultra-high dose of doxorubicin for hepatocellular carcinoma therapy. Theranostics 2019;9:2167-82. [PMID: 31149036 DOI: 10.7150/thno.30867] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 15.7] [Reference Citation Analysis]
38 Zhang X, Lin C, Chan W, Liu K, Lu A, Lin G, Hu R, Shi H, Zhang H, Yang Z. Dual-Functional Liposomes with Carbonic Anhydrase IX Antibody and BR2 Peptide Modification Effectively Improve Intracellular Delivery of Cantharidin to Treat Orthotopic Hepatocellular Carcinoma Mice. Molecules 2019;24:E3332. [PMID: 31547459 DOI: 10.3390/molecules24183332] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
39 Yu S, Hou Y, Hsu C, Tsai F, Tsai Y. Inclusion complex of emodin and glycyrrhetinic acid-conjugated-β-cyclodextrin to target liver cells: synthesis, characterization, and bioactivity in vitro and in vivo. J Incl Phenom Macrocycl Chem. [DOI: 10.1007/s10847-021-01123-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Zhu F, Wang BR, Zhu ZF, Wang SQ, Chai CX, Shang D, Li M. Photodynamic therapy: A next alternative treatment strategy for hepatocellular carcinoma? World J Gastrointest Surg 2021; 13(12): 1523-1535 [DOI: 10.4240/wjgs.v13.i12.1523] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Pranatharthiharan S, Patel MD, Malshe VC, Pujari V, Gorakshakar A, Madkaikar M, Ghosh K, Devarajan PV. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma. Drug Deliv 2017;24:20-9. [PMID: 28155331 DOI: 10.1080/10717544.2016.1225856] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 8.6] [Reference Citation Analysis]
42 Bai Z, Wei J, Yu C, Han X, Qin X, Zhang C, Liao W, Li L, Huang W. Non-viral nanocarriers for intracellular delivery of microRNA therapeutics. J Mater Chem B 2019;7:1209-25. [DOI: 10.1039/c8tb02946f] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 9.7] [Reference Citation Analysis]
43 Chakraborty S, Dlie ZY, Mukherjee B, Besra SE, Sengupta S, Sen R, Mukherjee A. A Comparative Investigation of the Ability of Various Aptamer-Functionalized Drug Nanocarriers to Induce Selective Apoptosis in Neoplastic Hepatocytes: In Vitro and In Vivo Outcome. AAPS PharmSciTech 2020;21:89. [PMID: 32026264 DOI: 10.1208/s12249-020-1629-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
44 Yamansarov EY, Lopatukhina EV, Evteev SA, Skvortsov DA, Lopukhov AV, Kovalev SV, Vaneev AN, Shkil' DO, Akasov RA, Lobov AN, Naumenko VA, Pavlova EN, Ryabaya OO, Burenina OY, Ivanenkov YA, Klyachko NL, Erofeev AS, Gorelkin PV, Beloglazkina EK, Majouga AG. Discovery of Bivalent GalNAc-Conjugated Betulin as a Potent ASGPR-Directed Agent against Hepatocellular Carcinoma. Bioconjug Chem 2021;32:763-81. [PMID: 33691403 DOI: 10.1021/acs.bioconjchem.1c00042] [Reference Citation Analysis]
45 Balasso A, Salmaso S, Pontisso P, Rosato A, Quarta S, Malfanti A, Mastrotto F, Caliceti P. Re-programming pullulan for targeting and controlled release of doxorubicin to the hepatocellular carcinoma cells. European Journal of Pharmaceutical Sciences 2017;103:104-15. [DOI: 10.1016/j.ejps.2017.02.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
46 Abudoureyimu M, Zhou H, Zhi Y, Wang T, Feng B, Wang R, Chu X. Recent progress in the emerging role of exosome in hepatocellular carcinoma. Cell Prolif 2019;52:e12541. [PMID: 30397975 DOI: 10.1111/cpr.12541] [Cited by in Crossref: 13] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
47 Venkatraj N, Nanjan MJ, Loyer P, Chandrasekar MJN, Cammas Marion S. Poly(malic acid) bearing Doxorubicin and N-Acetyl Galactosamine as a site-specific prodrug for targeting hepatocellular carcinoma. J Biomater Sci Polym Ed 2017;28:1140-57. [PMID: 28357894 DOI: 10.1080/09205063.2017.1311294] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
48 Zhou F, Shang W, Yu X, Tian J. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018;38:741-767. [PMID: 28621802 DOI: 10.1002/med.21455] [Cited by in Crossref: 87] [Cited by in F6Publishing: 100] [Article Influence: 17.4] [Reference Citation Analysis]
49 Zhang Q, Luo Q, Yuan X, Chai L, Li D, Liu J, Lv Z. Atmospheric particulate matter2.5 promotes the migration and invasion of hepatocellular carcinoma cells. Oncol Lett 2017;13:3445-50. [PMID: 28521450 DOI: 10.3892/ol.2017.5947] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
50 Wu MH, Chiu YF, Wu WJ, Wu PL, Lin CY, Lin CL, Hsieh YH, Liu CJ. Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression. Environ Toxicol 2018;33:1237-44. [PMID: 30187994 DOI: 10.1002/tox.22630] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
51 Nair AB, Shah J, Al-Dhubiab BE, Patel SS, Morsy MA, Patel V, Chavda V, Jacob S, Sreeharsha N, Shinu P, Attimarad M, Venugopala KN. Development of Asialoglycoprotein Receptor-Targeted Nanoparticles for Selective Delivery of Gemcitabine to Hepatocellular Carcinoma. Molecules 2019;24:E4566. [PMID: 31847085 DOI: 10.3390/molecules24244566] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
52 Rahman M, Almalki WH, Alrobaian M, Iqbal J, Alghamdi S, Alharbi KS, Alruwaili NK, Hafeez A, Shaharyar A, Singh T, Waris M, Kumar V, Beg S. Nanocarriers-loaded with natural actives as newer therapeutic interventions for treatment of hepatocellular carcinoma. Expert Opin Drug Deliv 2021;18:489-513. [PMID: 33225771 DOI: 10.1080/17425247.2021.1854223] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Xiao Y, Huang W, Zhu D, Wang Q, Chen B, Liu Z, Wang Y, Liu Q. Cancer cell membrane-camouflaged MOF nanoparticles for a potent dihydroartemisinin-based hepatocellular carcinoma therapy. RSC Adv 2020;10:7194-205. [DOI: 10.1039/c9ra09233a] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
54 Wei-Ze L, Wen-Xia H, Ning Z, Shu-Miao H, Fei L, Li-Na F, Zhan-Rui Z, Xi-Feng Z, Li-Bin Y. A novel embolic microspheres with micro nano binary progressive structure for transarterial chemoembolization applications. Eur J Pharm Sci 2020;153:105496. [PMID: 32736094 DOI: 10.1016/j.ejps.2020.105496] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Kunjiappan S, Pavadai P, Vellaichamy S, Ram Kumar Pandian S, Ravishankar V, Palanisamy P, Govindaraj S, Srinivasan G, Premanand A, Sankaranarayanan M, Theivendren P. Surface receptor‐mediated targeted drug delivery systems for enhanced cancer treatment: A state‐of‐the‐art review. Drug Dev Res 2021;82:309-40. [DOI: 10.1002/ddr.21758] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
56 Vene E, Barouti G, Jarnouen K, Gicquel T, Rauch C, Ribault C, Guillaume SM, Cammas-Marion S, Loyer P. Opsonisation of nanoparticles prepared from poly(β-hydroxybutyrate) and poly(trimethylene carbonate)-b-poly(malic acid) amphiphilic diblock copolymers: Impact on the in vitro cell uptake by primary human macrophages and HepaRG hepatoma cells. Int J Pharm 2016;513:438-52. [PMID: 27640247 DOI: 10.1016/j.ijpharm.2016.09.048] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
57 Pireddu R, Pibiri M, Valenti D, Sinico C, Fadda AM, Simbula G, Lai F. A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine. Int J Pharm 2018;537:257-67. [PMID: 29294323 DOI: 10.1016/j.ijpharm.2017.12.048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
58 Zhang X, Lin C, Lu A, Lin G, Chen H, Liu Q, Yang Z, Zhang H. Liposomes equipped with cell penetrating peptide BR2 enhances chemotherapeutic effects of cantharidin against hepatocellular carcinoma. Drug Deliv 2017;24:986-98. [PMID: 28644728 DOI: 10.1080/10717544.2017.1340361] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
59 Zhang X, Bi C, Chen Q, Xu H, Shi H, Li X. Structure elucidation of arabinogalactoglucan isolated from Sedum sarmentosum Bunge and its inhibition on hepatocellular carcinoma cells in vitro. Int J Biol Macromol 2021;180:152-60. [PMID: 33741368 DOI: 10.1016/j.ijbiomac.2021.03.051] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Karahaliloglu Z, Kilicay E, Hazer B. PLinaS-g-PEG coated magnetic nanoparticles as a contrast agent for hepatocellular carcinoma diagnosis. J Biomater Sci Polym Ed 2020;31:1580-603. [PMID: 32460649 DOI: 10.1080/09205063.2020.1764183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Varmazyar M, Habibi M, Amini M, Pordanjani AH, Afrand M, Vahedi SM. Numerical simulation of magnetic nanoparticle-based drug delivery in presence of atherosclerotic plaques and under the effects of magnetic field. Powder Technology 2020;366:164-74. [DOI: 10.1016/j.powtec.2020.02.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
62 Stecanella LA, Bitencourt APR, Vaz GR, Quarta E, Silva Júnior JOC, Rossi A. Glycyrrhizic Acid and Its Hydrolyzed Metabolite 18β-Glycyrrhetinic Acid as Specific Ligands for Targeting Nanosystems in the Treatment of Liver Cancer. Pharmaceutics 2021;13:1792. [PMID: 34834206 DOI: 10.3390/pharmaceutics13111792] [Reference Citation Analysis]
63 Wu CH, Lan CH, Wu KL, Wu YM, Jane WN, Hsiao M, Wu HC. Hepatocellular carcinoma-targeted nanoparticles for cancer therapy. Int J Oncol 2018;52:389-401. [PMID: 29207071 DOI: 10.3892/ijo.2017.4205] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
64 Xiong F, Zhang F, Jin Y, Weng Q, Song J, Zhou G, Shin D, Zheng C, Yang X. Orthotopic hepatic cancer: radiofrequency hyperthermia-enhanced intratumoral herpes simplex virus-thymidine kinase gene therapy. Oncotarget 2018;9:14099-108. [PMID: 29581830 DOI: 10.18632/oncotarget.23586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
65 Li Y, Yang D, Wang Y, Li Z, Zhu C. Co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency. Int J Nanomedicine 2019;14:301-15. [PMID: 30643408 DOI: 10.2147/IJN.S187888] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
66 Chen M, Zhou X, Chen R, Wang J, Ye RD, Wang Y, Wu C, Mahato RI. Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy. Materials Today 2019;25:66-87. [DOI: 10.1016/j.mattod.2018.10.040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
67 Jędrzak A, Grześkowiak BF, Golba K, Coy E, Synoradzki K, Jurga S, Jesionowski T, Mrówczyński R. Magnetite Nanoparticles and Spheres for Chemo- and Photothermal Therapy of Hepatocellular Carcinoma in vitro. Int J Nanomedicine 2020;15:7923-36. [PMID: 33116509 DOI: 10.2147/IJN.S257142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
68 Iqbal H, Yang T, Li T, Zhang M, Ke H, Ding D, Deng Y, Chen H. Serum protein-based nanoparticles for cancer diagnosis and treatment. J Control Release 2021;329:997-1022. [PMID: 33091526 DOI: 10.1016/j.jconrel.2020.10.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
69 Bartneck M, Schlößer CT, Barz M, Zentel R, Trautwein C, Lammers T, Tacke F. Immunomodulatory Therapy of Inflammatory Liver Disease Using Selectin-Binding Glycopolymers. ACS Nano 2017;11:9689-700. [PMID: 28829572 DOI: 10.1021/acsnano.7b04630] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
70 Mehmood T, Maryam A, Zhang H, Li Y, Khan M, Ma T. Deoxyelephantopin induces apoptosis in HepG2 cells via oxidative stress, NF-κB inhibition and mitochondrial dysfunction. Biofactors 2017;43:63-72. [PMID: 27628030 DOI: 10.1002/biof.1324] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
71 Ceballos MP, Rigalli JP, Ceré LI, Semeniuk M, Catania VA, Ruiz ML. ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma. Curr Med Chem 2019;26:1224-50. [PMID: 29303075 DOI: 10.2174/0929867325666180105103637] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]